C-myb表达与食管癌后程加速超分割放疗敏感性的研究

Analysis of the relation of C-myb with late course accelerated hyperfractional radiotherapy sensitivity in esophageal carcinoma

目的:探讨C-myb表达与食管癌后程加速超分割放疗(LCAF)的关系。方法:对106例食管癌患者根据C-myb表达分为阴性常规组、阴性后超组、阳性常规组和阳性后超组四个组,阴性及阳性常规组均进行常规分割放疗,2Gy/次,5次/周,至DT 60-64Gy/30-32次。阴性后超组和阳性后超组先进行常规分割放疗,方法同常规组,至DT 40Gy/20次后行后程加速超分割放疗,1.5Gy/次,2次/日,间隔6小时,每周5天,总剂量DT 65.4-67Gy/38-39次,5.8-6.2周。结果:阴性常规组及后超组、阳性常规组及后超组的3年局控率分为61.3%、68.0%、37.9%、52.4%;3年生存率分为32.3%、36.0%、13.8%、23.8%。结论:C-myb表达阴性者后程加速超分割放疗虽提高了疗效,但未达统计学意义。C-myb表达阳性者采用后程加速超分割放疗较常规分割放疗提高了疗效。

Objective：To discuss the relation of C-myb with late course accelerated hyperfractional radiotherapy （LCAF） sensitivity in esophageal carcinoma.Methods：Total of 106 patients were devided into four groups：C-myb negative conventional group（NC）,C-myb negative LCAF group（NL）,C-myb positive conventional group （PC）,C-myb positive LCAF group （PL）.Conventional groups were treated with radiotherapy,2Gy per day,5 sessions a week to a total dose of 60-64Gy.LCAF groups were treated with LCAF after 40Gy,to the total dose of 65.4-67Gy,1.5Gy per fraction,twice daily.Results：The 3-year local control rates were 61.3%,68.0%,37.9%,52.4%;The 3-year survival rates were 32.3%,36.0%,13.8%,23.8%.Conclusion：LCAF did not improve the survival in patients with C-myb negative,but improved the survival in patients with C-myb positive.